Respiratory syncytial virus
Benjamin G. Polkinghorne A , Craig M. Mellis B and Alison M. Kesson C
+ Author Affiliations
- Author Affiliations
A NSW Public Health Officer Training Program, NSW Department of Health
B Central Clinical School, Faculty of Medicine, The University of Sydney
C Infectious Diseases and Microbiology, The Children’s Hospital at Westmead
NSW Public Health Bulletin 22(8) 159-159 https://doi.org/10.1071/NB11022
Published: 20 September 2011
References
[1] Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289 179–86.| Mortality associated with influenza and respiratory syncytial virus in the United States.Crossref | GoogleScholarGoogle Scholar |
[2] Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 2003; 143 S112–7.
| Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection.Crossref | GoogleScholarGoogle Scholar |
[3] Groothuis J, Bauman J, Malinoski F, Eggleston M. Strategies for prevention of RSV nosocomial infection. J Perinatol 2008; 28 319–23.
| Strategies for prevention of RSV nosocomial infection.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD1c3ot1ehug%3D%3D&md5=878d999822c1f5e9be3063456dce7f2bCAS |
[4] The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102 531–7.
| Palivizumab, a humanized respiratory syncytial virus monoclonal antibody reduces hospitalization from respiratory syncytial virus infection in high-risk infants.Crossref | GoogleScholarGoogle Scholar |
[5] Kesson AM. Respiratory virus infections. Paediatr Respir Rev 2007; 8 240–8.
| Respiratory virus infections.Crossref | GoogleScholarGoogle Scholar |
